Non-alcoholic fatty liver disease: further expression of the metabolic syndrome (Q36734086)

16 August 2017

1 reference

title

Non-alcoholic fatty liver disease: further expression of the metabolic syndrome (English)

1 reference

metabolic dysfunction–associated steatotic liver disease

16 August 2017

1 reference

0 references

1 reference

based on heuristic

inferred from title

non-alcoholic fatty liver

1 reference

1 reference

Giovanni Tarantino

1 reference

16 August 2017

Gennaro Saldalamacchia

series ordinal

1 reference

16 August 2017

Paolo Conca

series ordinal

1 reference

16 August 2017

Adriano Arena

series ordinal

1 reference

16 August 2017

publication date

1 March 2007

1 reference

Journal of Gastroenterology and Hepatology

16 August 2017

published in

1 reference

16 August 2017

1 reference

16 August 2017

1 reference

16 August 2017

page(s)

293-303

1 reference

Comparison of CT and dual-energy DEXA using a modified trunk compartment in the measurement of abdominal fat.

16 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1746.2007.04824.X

Misclassification of high-risk older subjects using waist action levels established for young and middle-aged adults--results from the Rotterdam Study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1746.2007.04824.X

Metabolic and vascular abnormalities in subjects at risk for type 2 diabetes: the early start of a dangerous situation

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1746.2007.04824.X

Obesity and depression: results from the longitudinal Northern Finland 1966 Birth Cohort Study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1746.2007.04824.X

The hOGG1 Ser326Cys gene polymorphism is associated with decreased insulin sensitivity in subjects with normal glucose tolerance

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1746.2007.04824.X

Comparative evaluation of simple insulin sensitivity methods based on the oral glucose tolerance test

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1746.2007.04824.X

Histopathology of pediatric nonalcoholic fatty liver disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1746.2007.04824.X

Motion - all patients with NASH need to have a liver biopsy: arguments against the motion

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1746.2007.04824.X

Elevated free IGF-I levels in prepubertal Hispanic girls with premature adrenarche: relationship with hyperandrogenism and insulin sensitivity

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1746.2007.04824.X

The emerging epidemic of obesity in developing countries.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1746.2007.04824.X

Nonalcoholic fatty liver disease: predictors of nonalcoholic steatohepatitis and liver fibrosis in the severely obese

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1746.2007.04824.X

NASH and insulin resistance: Insulin hypersecretion and specific association with the insulin resistance syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1746.2007.04824.X

Nonalcoholic steatohepatitis, insulin resistance, and metabolic syndrome: further evidence for an etiologic association

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1746.2007.04824.X

Non-alcoholic steatohepatitis (NASH): where are we now and where are we going?

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1746.2007.04824.X

The keratin cytoskeleton in liver diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1746.2007.04824.X

Ethnic differences in the prevalence of cryptogenic cirrhosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1746.2007.04824.X

Non-alcoholic steatohepatitis in type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1746.2007.04824.X

Rad: a member of the Ras family overexpressed in muscle of type II diabetic humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1746.2007.04824.X

Bezafibrate for tamoxifen-induced non-alcoholic steatohepatitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1746.2007.04824.X

Mitochondria in nonalcoholic fatty liver disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1746.2007.04824.X

Inhibition of insulin receptor gene expression and insulin signaling by fatty acid: interplay of PKC isoforms therein

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1746.2007.04824.X

Effect of short-term, low dose aspirin supplementation on the activation of pro-inflammatory NF-kappaB in aged rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1746.2007.04824.X

Evaluation of liver fatty acid oxidation in the leptin-deficient obese mouse.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1746.2007.04824.X

Upregulation of proinflammatory and proangiogenic cytokines by leptin in human hepatic stellate cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1746.2007.04824.X

Cytokines and NASH: a pilot study of the effects of lifestyle modification and vitamin E.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1746.2007.04824.X

Hepatocyte CYP2E1 overexpression and steatohepatitis lead to impaired hepatic insulin signaling.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1746.2007.04824.X

Acute inhibition of hepatic beta-oxidation in APOE*3Leiden mice does not affect hepatic VLDL secretion or insulin sensitivity

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1746.2007.04824.X

Apolipoprotein synthesis in nonalcoholic steatohepatitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1746.2007.04824.X

Peroxisomal proliferator activated receptor-gamma deficiency in a Canadian kindred with familial partial lipodystrophy type 3 (FPLD3)

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1746.2007.04824.X

Hepatic steatosis in Dunnigan-type familial partial lipodystrophy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1746.2007.04824.X

The role of oxidative stress in NASH and fatty liver model

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1746.2007.04824.X

Total body metabolism of 13C-octanoic acid is preserved in patients with non-alcoholic steatohepatitis, but differs between women and men.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1746.2007.04824.X

Steatotic liver allografts up-regulate UCP-2 expression and suffer necrosis in rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1746.2007.04824.X

Leptin regulates insulin sensitivity via phosphatidylinositol-3-OH kinase signaling in mediobasal hypothalamic neurons.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1746.2007.04824.X

Immunohistochemical evidence of functional leptin receptor expression in neuronal and endothelial cells of the rat brain

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1746.2007.04824.X

Glutathione-enhancing agents protect against steatohepatitis in a dietary model

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1746.2007.04824.X

Mechanisms of Disease: pathogenesis of nonalcoholic fatty liver disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1746.2007.04824.X

Design and validation of a histological scoring system for nonalcoholic fatty liver disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1746.2007.04824.X

Other disease associations with non-alcoholic fatty liver disease (NAFLD).

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1746.2007.04824.X

Fat-containing lesions of the liver: cross-sectional imaging findings with emphasis on MRI.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1746.2007.04824.X

The utility of radiological imaging in nonalcoholic fatty liver disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1746.2007.04824.X

Imaging of diffuse liver disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1746.2007.04824.X

The use of orlistat in the treatment of obesity, dyslipidaemia and Type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1746.2007.04824.X

Orlistat for the long-term treatment of obesity

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1746.2007.04824.X

Histologic study of colonic mucosa in patients with chronic diarrhea and normal colonoscopic findings.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1746.2007.04824.X

Glutamine supplementation of parenteral nutrition does not improve intestinal permeability, nitrogen balance, or outcome in newborns and infants undergoing digestive-tract surgery: results from a double-blind, randomized, controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1746.2007.04824.X

Vitamin E modulates radiation-induced oxidative damage in mice fed a high-lipid diet

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1746.2007.04824.X

Efficacy and safety of ursodeoxycholic acid versus cholestyramine in intrahepatic cholestasis of pregnancy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1746.2007.04824.X

Opposite action of S-adenosyl methionine and its metabolites on CYP2E1-mediated toxicity in pyrazole-induced rat hepatocytes and HepG2 E47 cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1746.2007.04824.X

Pathophysiological basis for antioxidant therapy in chronic liver disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1746.2007.04824.X

Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1746.2007.04824.X

Rosiglitazone reduces insulin requirement and C-reactive protein levels in type 2 diabetic patients receiving peritoneal dialysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1746.2007.04824.X

Peroxisome proliferator-activated receptor gamma as a drug target in the pathogenesis of insulin resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1746.2007.04824.X

Evidence against a role for insulin-signaling proteins PI 3-kinase and Akt in insulin resistance in human skeletal muscle induced by short-term GH infusion

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1746.2007.04824.X

Adherence with pharmacotherapy for type 2 diabetes: a retrospective cohort study of adults with employer-sponsored health insurance

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1746.2007.04824.X

Time course of GLUT4 and AMPK protein expression in human skeletal muscle during one month of physical training

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1746.2007.04824.X

Exercise training increases glycogen synthase activity and GLUT4 expression but not insulin signaling in overweight nondiabetic and type 2 diabetic subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1746.2007.04824.X

Efficacy and safety of troglitazone in the treatment of lipodystrophy syndromes

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1746.2007.04824.X

A randomized controlled trial of metformin versus vitamin E or prescriptive diet in nonalcoholic fatty liver disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1746.2007.04824.X

Metformin therapy increases insulin-stimulated release of D-chiro-inositol-containing inositolphosphoglycan mediator in women with polycystic ovary syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1746.2007.04824.X

Acarbose attenuates the hypotensive response to sucrose and slows gastric emptying in the elderly

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1746.2007.04824.X

Acarbose in obese patients with polycystic ovarian syndrome: a double-blind, randomized, placebo-controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1746.2007.04824.X

Acarbose for the treatment of impared glucose tolerance?

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1746.2007.04824.X

Improved glycemic control and lipid profile in a randomized study of pioglitazone compared with acarbose in patients with type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1746.2007.04824.X

Enhanced circadian ACTH release in obese premenopausal women: reversal by short-term acipimox treatment.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1746.2007.04824.X

Incidence and risk factors for non-alcoholic steatohepatitis: prospective study of 5408 women enrolled in Italian tamoxifen chemoprevention trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1746.2007.04824.X

Effects of tamoxifen on hepatic fat content and the development of hepatic steatosis in patients with breast cancer: high frequency of involvement and rapid reversal after completion of tamoxifen therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1746.2007.04824.X

Radiation sensitiser effective against liver disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1746.2007.04824.X

Limitation of combination therapy of interferon and ribavirin for older patients with chronic hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1746.2007.04824.X

Laparoscopic bariatric surgery

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1746.2007.04824.X

Sampling Variability of Liver Biopsy in Nonalcoholic Fatty Liver Disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1746.2007.04824.X

10.1111/J.1440-1746.2007.04824.X

21 January 2018

Identifiers

DOI

1 reference

16 August 2017

1 reference